X

Trial Profile

Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S-49076 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Servier

Most Recent Events

01 Aug 2017 Results published in the European Journal of Cancer.
01 Nov 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
23 Oct 2013 Interim results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com